Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.41 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.41 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 12/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | FUT7 | Q11130 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | SELL | P14151 | 2/20 | 0.41 |
| ▸ | SELP | P16109 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18717467 | 0.98 | RECQL (0.50) | RECQLKDM1AKDM4ELMNATDP1 | |
| SCHEMBL4168968 | 0.98 | RECQL (0.50) | RECQLKDM1AKDM4ELMNATDP1 | |
| SCHEMBL4168972 | 0.98 | RECQL (0.50) | RECQLKDM1AKDM4ELMNATDP1 | |
| SCHEMBL31716495 | 0.79 | KDM1A (0.46) | RECQLKDM1ALMNAGAAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4168213 | 0.77 | KDM1A (0.62) | RECQLKDM1AKDM4ELMNAMAPT | |
| SCHEMBL8121974 | 0.76 | TTR (0.48) | RECQLKDM1AALDH1A1HPGDMAPK1 | |
| SCHEMBL3237528 | 0.74 | TTR (0.46) | RECQLKDM1ALMNATDP1ALDH1A1 | |
| SCHEMBL12433083 | 0.74 | KDM1A (0.65) | RECQLKDM1AKDM4EMAPTCA12 | |
| SCHEMBL1338633 | 0.74 | LMNA (0.44) | RECQLKDM1AKDM4ELMNAALDH1A1 | |
| SCHEMBL18717464 | 0.74 | KDM1A (0.65) | RECQLKDM1AKDM4EMAPTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0144396-B1 | POLYHYDROXYBENZOIC ACID DERIVATIVES | VAN'T RIET, Bartholomeus (US) | 1991-01-02 | — | — | EP | claimed |
| EP-0144396-A4 | POLYHYDROXYBENZOIC ACID DERIVATIVES. | RIET BARTHOLOMEUS VAN T (US) | 1986-08-21 | — | — | EP | claimed |
| EP-0144396-A1 | POLYHYDROXYBENZOIC ACID DERIVATIVES. | RIET BARTHOLOMEUS VAN T (US) | 1985-06-19 | — | — | EP | claimed |
| WO-1984004676-A1 | POLYHYDROXYBENZOIC ACID DERIVATIVES | RIET BARTHOLOMEUS VAN T | 1984-12-06 | — | — | WO | claimed |
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2017-04-13 | — | — | US | disclosed |
| US-9526707-B2 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2030615-A2 | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | ELFORD, Howard L. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L | 2009-02-19 | — | — | US | disclosed |
| US-5350770-A | Administering hydroxy benzamide derivative | ELFORD HOWARD L (US) | 1994-09-27 | — | — | US | disclosed |
| WO-1994002135-A1 | THERAPEUTIC PROCESS FOR THE TREATMENT OF SEPTIC SHOCK | ELFORD HOWARD L (US) | 1994-02-03 | — | — | WO | disclosed |
| US-5183828-A | Ribonucleotide reductase inhibitor and free radical scavenger | RIET BARTHOLOMEUS VAN T (US) | 1993-02-02 | — | — | US | disclosed |
| EP-0144396-B1 | POLYHYDROXYBENZOIC ACID DERIVATIVES | VAN'T RIET, Bartholomeus (US) | 1991-01-02 | — | — | EP | disclosed |
| US-4942253-A | INHIBITORS OF RIBONUCLEOTIDE REDUCTASE, ANTITUMOR AGENTS, LEUKEMIA, FREE RADICAL SCAVENGERS | RIET BARTHOLOMEUS VAN T (US) | 1990-07-17 | — | — | US | disclosed |
| US-4623659-A | RIBONUCLEOTIDE REDUCTASE INHIBITORS | RIET BARTHOLOMEUS VAN T (US) | 1986-11-18 | — | — | US | disclosed |
| EP-0144396-A4 | POLYHYDROXYBENZOIC ACID DERIVATIVES. | RIET BARTHOLOMEUS VAN T (US) | 1986-08-21 | — | — | EP | disclosed |
| EP-0144396-A1 | POLYHYDROXYBENZOIC ACID DERIVATIVES. | RIET BARTHOLOMEUS VAN T (US) | 1985-06-19 | — | — | EP | disclosed |
| WO-1984004676-A1 | POLYHYDROXYBENZOIC ACID DERIVATIVES | RIET BARTHOLOMEUS VAN T | 1984-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | CA2 3757/4885DPP4 1052/4885GAA 1275/4885 |
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | CA2 3757/4885DPP4 1052/4885GAA 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.